UPDATE 1-Sanofi test shows lixisenatide doesn't increase cardiovascular risk
March 19, 2015 at 04:35 AM EDT
PARIS, March 19 (Reuters) - Sanofi's lixisenatide drug for the treatment of type 2 diabetes does not increase cardiovascular risk among high risk patients, the French drugmaker said on Thursday.
